argenx SE
NASDAQ:ARGX

Watchlist Manager
argenx SE Logo
argenx SE
NASDAQ:ARGX
Watchlist
Price: 591.99 USD 2.88% Market Closed
Market Cap: 35.4B USD

EV/EBITDA
Enterprise Value to EBITDA

139
Current
0
Median
5.1
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
139
=
Enterprise Value
27.8B EUR
/
EBITDA
235.3m USD
Market Cap EV/EBITDA
NL
argenx SE
NASDAQ:ARGX
30.6B USD 139
FR
Pharnext SCA
OTC:PNEXF
6T USD -194 537.7
US
Abbvie Inc
NYSE:ABBV
336.1B USD 15.4
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 213.5
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 14.8
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 10.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 26
US
Epizyme Inc
F:EPE
94.1B EUR -580.7
AU
CSL Ltd
ASX:CSL
131.1B AUD 19.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 12.1
US
Seagen Inc
F:SGT
39.3B EUR -66.6
EBITDA Growth EV/EBITDA to Growth
NL
argenx SE
NASDAQ:ARGX
Average EV/EBITDA: 33.8
139
727%
0.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 537.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
40.4
2-Years Forward
EV/EBITDA
23.2
3-Years Forward
EV/EBITDA
16.4